Stocktoria
PERRIGO Co plc PRGO
NYSE · stock · Pharmaceutical Preparations · website · IPO 1991-12-17
PERRIGO Co plc financials (annual)
Bars are annual figures from 2016 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.3B | $4.4B | $4.7B | $4.5B | $4.1B | $4.1B | $3.9B | $4.7B | $4.9B | $5.3B |
| Gross profit | $1.5B | $1.5B | $1.7B | $1.5B | $1.4B | $1.5B | $1.4B | $1.8B | $2.0B | $2.1B |
| R&D expense | $95.4M | $112.2M | $122.5M | $123.1M | $122.0M | $121.7M | $119.2M | $218.6M | $167.7M | $184.0M |
| Operating income | -$1.1B | $112.9M | $151.9M | $78.9M | $410.4M | $265.2M | $174.7M | $236.5M | $598.2M | -$2.0B |
| Income tax | $104.4M | $80.0M | -$3.9M | -$8.2M | $389.6M | -$38.3M | -$10.7M | $159.6M | $160.5M | -$835.5M |
| Net income | -$1.4B | -$171.8M | -$12.7M | -$140.6M | -$68.9M | -$162.6M | $146.1M | $131.0M | $119.6M | -$4.0B |
| EPS (diluted) | $-10.29 | $-1.25 | $-0.09 | $-1.04 | $-0.52 | $-1.19 | $1.07 | $0.95 | $0.84 | $-28.01 |
| Operating cash flow | $238.5M | $362.9M | $405.5M | $307.3M | $156.3M | $636.2M | $387.8M | $593.0M | $698.9M | $654.9M |
| Free cash flow | $145.1M | $244.6M | $303.8M | $210.9M | $4.2M | $465.8M | $250.1M | $490.4M | $610.3M | $548.7M |
| Cash & equivalents | — | $558.8M | $751.3M | $600.7M | $1.9B | $631.5M | $354.3M | $551.1M | $678.7M | $622.3M |
| Inventory | $1.1B | $1.1B | $1.1B | $1.2B | $1.0B | $1.1B | $967.3M | $878.0M | $806.9M | $795.0M |
| Total assets | $8.5B | $9.6B | $10.8B | $11.0B | $10.4B | $11.5B | $11.3B | $11.0B | $11.6B | $13.9B |
| Total liabilities | $5.6B | $5.3B | $6.0B | $6.2B | $5.3B | $5.8B | $5.5B | $5.3B | $5.5B | $7.9B |
| Shareholders' equity | $2.9B | $4.3B | $4.8B | $4.8B | $5.2B | $5.7B | $5.8B | $5.7B | $6.2B | $6.0B |
Growth · year-over-year · Revenue CAGR -2.4%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth | -2.8% | -6.1% | +4.6% | +7.6% | +1.2% | +5.6% | -18.2% | -4.3% | -6.3% | +24.9% |
| Net income growth | — | — | — | — | — | -211.3% | +11.5% | +9.5% | — | -3048.4% |
| EPS growth | — | — | — | — | — | -211.2% | +12.6% | +13.1% | — | -2987.6% |
| Free cash flow growth | -40.7% | -19.5% | +44.0% | +4921.4% | -99.1% | +86.2% | -49.0% | -19.6% | +11.2% | -23.6% |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.